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OBJECTIVES Focus of the current study was on the significance of bacterial endotoxin, which shows a
variety of pro-atherogenic properties and may occur at high concentration in the circulation
of infected subjects.
BACKGROUND The possibility of an infectious risk factor in atherogenesis and cardiovascular disease has
stimulated research interest, but the nature of such process remains obscure.
METHODS We measured plasma endotoxin levels (LAL assay) in a random population of 516 men and
women 50 to 79 years old at the 1990 baseline evaluation (Bruneck Study). End points of this
prospective survey were incident (early) atherosclerosis in the carotid arteries as assessed with
high-resolution Duplex ultrasound (five-year follow-up rate, 98%) and incident cardiovascu-
lar disease (follow-up rate, 100%).
RESULTS Median endotoxin concentration amounted to 14.3 pg/ml (range, 6.0 to 209.2 pg/ml).
Subjects with levels beyond 50 pg/ml (90th percentile) faced a threefold risk of incident
atherosclerosis (odds ratio [95% confidence interval] 2.9 [1.4–6.3]; p , 0.01). The risk
associated with high endotoxin was most pronounced in subjects with chronic infections and
in current and ex-smokers. Notably, smokers with low endotoxin levels and nonsmokers did
not differ in their atherosclerosis risk, whereas smokers with high levels almost invariably
developed new lesions. All findings emerged as independent of vascular risk factors. Similar
results were obtained for incident cardiovascular disease.
CONCLUSIONS The current study yields first epidemiologic evidence that endotoxemia constitutes a strong
risk factor of early atherogenesis in subjects with chronic or recurrent bacterial infections and
a link in the association between cigarette smoking and atherosclerotic disease. (J Am Coll
Cardiol 1999;34:1975–81) © 1999 by the American College of Cardiology
Circulating bacterial endotoxin (ETX) is well-established to
provoke severe endothelial dysfunction and exhibits a variety
of pro-atherogenic properties (1– 6). Contra previous
knowledge, prominent endotoxemia is not confined to
sepsis but also occurs in apparently healthy subjects (7).
Chronic or recurrent bacterial infections, smoker’s bronchi-
tis and gut barrier dysfunction all may be rich sources of
circulating ETX (7–9).
See page 1982
A growing body of evidence supports the concept that
systemic inflammation plays a role in the initiation and
progression of atherosclerosis and its complications. Plasma
markers for underlying systemic inflammation such as
C-reactive protein were shown to be risk predictors for
future myocardial infarction or stroke (10). The inflamma-
tory signals driving immunologic activity in atherosclerosis
are unknown. They may be nonantigenic or antigenic but of
noninfectious origin (10). We hypothesize that sustained
exposure to high ETX levels in the clinical settings (men-
tioned previously) constitutes a prominent risk factor of
early atherogenesis. The Bruneck Study, a prospective
population survey on the course and etiology of atheroscle-
rosis, offers a unique possibility to clarify this issue from an
epidemiological perspective.
METHODS
Study subjects. The current evaluation was performed as
part of the Bruneck Study (11,12). The survey area is
located in the north of Italy (Bolzano Province). Agricul-
ture, tourism, commerce, and light industry are the main
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sources of income. Geographic remoteness causes low pop-
ulation mobility (,0.2%/year). Plasma ETX levels were
assessed in a random subsample of the Bruneck Study
population. In brief, 86 men and 86 women each in their
sixth to eighth decade were enrolled at the baseline exam-
ination (July to November 1990) after they had given their
informed consent to join this study (n 5 516). During
follow-up, 41 subjects died. A total of six participants
changed their residence within the Bruneck area and re-
mained eligible. Among survivors (n 5 475) follow-up was
98% complete for ultrasonographic reevaluation (July to
October 1995; n 5 466). Reliable data on fatal and nonfatal
cardiovascular disease were available in virtually all subjects.
Clinical history and examination. All participants under-
went a clinical examination with cardiologic and neurologic
priority (12). Regular alcohol consumption was quantified
in terms of grams per day. Systolic and diastolic blood
pressures were taken with a standard mercury sphygmoma-
nometer after at least 10 min of rest while the subject was in
a sitting position. The values used in the current analysis
were means of three measurements taken by the same
investigator at about 1-h intervals. Hypertension was de-
fined by a blood pressure $160/95. A standardized oral
glucose tolerance test (75 g glucose in 10% solution) was
performed in all subjects except those with well-established
diabetes mellitus. Diabetes mellitus was coded present for
subjects with fasting glucose levels .7.8 mmol/liter (140
mg/dl) and/or a 2-h value .11.1 mmol/liter (200 mg/dl).
Body mass index was calculated as weight divided by height
squared. The number of cigarettes smoked and the pack-
years were recorded for each smoker and ex-smoker. Life-
time nonsmokers and ex-smokers who quit more than 5
years before entering the study (1990) were referred to as
current nonsmokers.
Myocardial infarction was deemed confirmed when
World Health Organization criteria for definite disease
status (13) were met, including compatible symptoms and
either electrocardiographic changes or elevated cardiac en-
zymes. Stroke and transient ischemic attacks were classified
according to the criteria of the National Survey of Stroke
(14). The diagnosis of peripheral artery disease required a
positive response to the Rose questionnaire, with the vas-
cular nature of complaints confirmed by standard diagnostic
procedures. Self-reported data were verified from hospital
records, death certificates and information from general
practitioners and supplemented by a thorough screening of
the hospital database for arterial diseases to minimize recall
bias and selective nonresponding.
In an effort to identify subjects with chronic bacterial
infections or clinical conditions known to be associated with
recurrent episodes of infectious exacerbation (asthma, em-
physema), we commenced an extensive screening consisting
of two consecutive phases. The first step involved a detailed
self-reported medical and medication history, full clinical
examination, spirometry, extensive laboratory evaluations
including assessment of acute-phase reactants, markers of
chronic infections and urinary analysis and a thorough
review of Bruneck Hospital databases and medical records
provided by general practitioners. In a second step, individ-
uals suspected of having diseases of interest were referred for
further optional examinations such as chest X-ray, endos-
copy and serological examinations. A definite diagnosis was
established applying standard diagnostic guidelines.
Laboratory methods. Blood samples were taken from the
antecubital vein after subjects had fasted and abstained from
smoking for at least 12 h (12). In the event of acute
infections, blood samples were drawn up to six weeks later.
Apolipoproteins were measured using a nephelometric
fixed-time method (apolipoprotein AI and B, Behring;
coefficients of variation [CV] 5.7% and 2.4%, respectively).
High-density lipoprotein (HDL) cholesterol was deter-
mined enzymatically (CHOD-PAP method, Merck; CV
2.2% to 2.4%). Low-density lipoprotein (LDL) cholesterol
was calculated with the Friedewald formula except in
subjects with triglycerides .4.52 mmol/liter. Lipoprotein(a)
(ELISA, Immuno; CV 3.5% to 6.3%), serum protein
(biuret method; Merck), ferritin (fluorometric enzyme im-
munoassay, Baxter; CV 5.0% to 5.9%) and other variables
were assessed according to standard procedures.
Endotoxin-levels were quantified using the chromogenic
Limulus amebocyte lysate (LAL) test for ETX measure-
ments in plasma samples (Chromogenix, Mo¨lndal, Sweden)
according to the manufacturer’s instructions, as previously
described (15). In brief, the LAL contains an enzyme
system that is activated in the presence of ETX. The
activated enzymes split off para-nitro aniline from the
chromogenic substrate to produce a yellow color, giving the
opportunity to measure photometrically (405 nm) the
amount of ETX present in the system. Single measurements
of aliquoted plasma samples were performed. A standard
curve showing linear correlation between increasing absor-
bances and log concentrations of standard ETX was used to
determine the ETX concentrations in unknown heat-
treated samples. Data were calculated and transformed to
pg/mL plasma ETX.
Scanning protocol and definition of ultrasound end
points. The ultrasound protocol involves the scanning of
the internal (bulbous and distal segments) and common
carotid arteries (proximal and distal segments) of either side
with a 10-MHz imaging probe and a 5-MHz Doppler.
Atherosclerotic lesions were defined by two ultrasound
Abbreviations and Acronyms
CV 5 coefficient of variation
ETX 5 endotoxin
HDL 5 high-density lipoprotein
LAL 5 Limulus amebocyte lysate
LDL 5 low-density lipoprotein
ln 5 log-normalized
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criteria: i) wall surface (protrusion into the lumen or
roughness of the arterial boundary) and ii) wall texture
(echogenicity). Presence and maximum axial diameter of
plaques were assessed in each of the eight vessel segments.
An atherosclerosis summing score was calculated by adding
all plaque diameters (12). Scanning was performed twice in
1990 and 1995 by the same experienced sonographer, who
was unaware of the subjects’ clinical and laboratory charac-
teristics. The ultrasound method applied permitted us to
monitor atherosclerosis in individuals (person-based ap-
proach) and to differentiate various stages of atherosclerosis
progression (11). The current analysis focused on incident
(early) atherosclerosis as the putative target of ETX attack.
Reproducibility of this ultrasound end point was nearly
perfect (16) as indicated by a kappa coefficient of agreement
of 0.89 (double measurements, n 5 100).
Statistics. Incidence rates of atherosclerosis were expressed
as events per 1,000 person-years (incidence density) (17).
Strength and type of association between plasma ETX level
and incident atherosclerosis were assessed by logistic regres-
sion analysis. The test procedure was based on maximum
likelihood estimators (18). To account for deviations from
the normal distribution, ETX concentrations were log-
normalized (ln). Multivariate regression models were built
with either a forward stepwise selection procedure applying
the default settings of the SPSS-X statistical software (19)
or with forced entry of a fixed set of covariates including
vascular risk factors and potential determinants of ETX
level. Results were virtually identical. For ease of presenta-
tion, we provide data derived from the latter approach only
(Tables 1 and 2). Separate equations were calculated for
smokers and subjects with chronic infections. Effect modi-
fication was examined by the inclusion of interaction terms.
In an attempt to obtain the most suitable parametric scale of
association, 10 equally sized categories of plasma ETX
concentrations were modeled with indicator variables in
separate analyses. Trends were estimated by visual inspec-
tion of plots of the logit (log odds) against the midpoints of
deciles. Finally, crude and adjusted hazard ratios of incident
cardiovascular disease were calculated with Cox models
(20). The proportional hazard assumptions were satisfied.
RESULTS
Five-year incidence of carotid atherosclerosis in our study
population amounted to 103 per 1,000 person-years. Corre-
sponding rates for incident cardiovascular disease and cardio-
vascular mortality were 10.8 and 3.9, respectively, per 1,000
person-years. For descriptive purposes Table 1 depicts main
demographic characteristics, levels of selected vascular risk
factors and ETX separately in subjects with and without
incident atherosclerosis. Three out of five men and one out of
five women reported current or previous cigarette smoking.
Virtually all plasma specimens contained bacterial ETX
(median, 14.3 pg/ml; interquartile range, 10.6 –19.8)
though at highly variable concentrations (range, 6.0 to 209.2
pg/ml; for distribution, see Fig. 1). Levels were on average
22% higher in women than in men (p 5 0.001) and
positively correlated with total protein concentrations (36%
increase for each 1 g/dl-increment of serum protein; p 5
0.011) and cigarette smoking (10% increase per 10 ciga-
rettes; p 5 0.006).
Table 1. Association of Potential Vascular Risk Factors With Incident Atherosclerosis
Characteristic
Incident Carotid Atherosclerosis (5-
year)
p Value
p Value (Adjusted for
Age/Gender)No (n 5 227) Yes (n 5 239)
Male gender, n (%) 87 (41.3) 129 (54.0) 0.006 —
Age, yrs 60.3 6 8.3* 65.8 6 8.1 , 0.001 —
Apolipoprotein B, mg/dl 118.9 6 31.2 129.9 6 46.8 0.003 0.012
Apolipoprotein AI, mg/dl 165.8 6 27.3 162.6 6 32.4 0.260 0.170
Lipoprotein(a), mg/dl 14.7 6 14.9 16.9 6 19.7 0.170 0.093
Ferritin, ng/ml 139.1 6 138.4 181.1 6 193.4 , 0.001 0.008
Blood pressure systolic, mm Hg 144.9 6 19.5 153.1 6 22.3 , 0.001 0.001
Hypertension, n (%) 62 (27.8) 108 (45.2) , 0.001 0.010
Body mass index, kg/m2 25.3 6 3.9 25.1 6 3.7 0.590 0.970
Diabetes mellitus, n (%) 19 (8.5) 30 (12.6) 0.150 0.710
Alcohol consumption, n (%) — — 0.004 0.030
#50 g/d 64 (28.7) 59 (24.7) — —
51–99 g/d 17 (7.6) 44 (18.4) — —
$100 g/d 20 (9.0) 27 (11.3) — —
Smoking, pack-years 17.9 6 16.5 27.8 6 15.3 , 0.001 0.017
White blood cells, 1000/ml 6.2 6 1.7 6.5 6 1.6 0.068 0.110
C-reactive protein, mg/dl 0.24 6 0.73 0.45 6 0.86 0.008 0.090
Endotoxin, pg/ml 20.4 6 22.6 29.6 6 43.2 0.005 0.002
n 5 number of subjects; *mean 6 standard deviation.
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In the risk analysis ln-transformed ETX concentrations
were applied rather than native data to account for devia-
tions from the normal distribution. The ln-ETX emerged as
a significant and independent risk predictor of five-year
incidence of carotid atherosclerosis. In an effort to charac-
terize type and scale of association, analysis was repeated after
categorizing ETX levels into 10 equally spaced groups (de-
ciles). Figure 2 demonstrates a clear-cut binary-type associa-
tion, with the excess risk confined to the highest decile
(threshold, 50 pg/ml). All results remained virtually unchanged
when subjects with prevalent cardiovascular disease (n 5 47)
and/or regular medication (n 5 281) and/or gastrointestinal
ulcers (n 5 26) and/or malign neoplasm (n 5 30) were
excluded. Sample size does not allow potential modifying
effects of aspirin treatment to be established.
As an outstanding finding, the association between en-
dotoxemia and incident atherosclerosis was especially rele-
vant to current and ex-smokers (Table 2, Fig. 3) (p , 0.001
for effect modification). In this subgroup of particular
interest (n 5 196) the scale-fitting procedure described
above replicated the results obtained in the entire popula-
tion sample (Fig. 2, lower panel), that is, revealed a clear-cut
binary association with the threshold for the switch in
atherosclerosis risk identified as 50 pg/ml (90th percentile).
In current and ex-smokers, measurement of ETX permitted
us to accurately identify subjects at high risk of incident
(active) atherosclerosis. As visualized in Figure 4, age- and
sex-adjusted incidence rates of atherosclerosis in smokers
with ETX levels #50 pg/ml were no higher than those of
non-smokers, whereas almost all smokers with ETX levels
.50 pg/ml developed new lesions within the five-year
follow-up period. Except for smoking, the association be-
Figure 1. Frequency distribution of endotoxin levels (pg/ml) (n 5
516).
Figure 2. Binary-type association between endotoxin plasma level
and atherosclerosis risk. OR 5 odds ratio; AS 5 atherosclerosis.
Table 2. Risk of Incident Atherosclerosis by Plasma Endotoxin Levels
ETX*
p
Value ETX <50 ETX >50
p
Value
All subjects, n 5 466
Cases, n (%) — — 208 (49) 31 (74) —
Odds ratio (95% CI)
Adjusted age/gender/baseline AS 1.4 (1.1–1.7) 0.005 1.0 2.9 (1.4–6.3) 0.005
Multivariate adjustment 1.3 (1.1–1.7) 0.016 1.0 3.3 (1.5–7.5) 0.003
Smokers/Ex-Smokers, n 5 196
Cases, n (%) — — 95 (53) 16 (84) —
Odds ratio (95% CI)
Adjusted age/sex/baseline AS 1.7 (1.2–2.3) 0.007 1.0 9.4 (2.3–39.8) 0.002
Multivariate adjustment 1.7 (1.2–2.5) 0.008 1.0 13.2 (2.9–61.3) 0.001
Odds ratios and 95% confidence intervals (CI) were derived from logistic regression analyses of incident atherosclerosis on endotoxin (ETX) levels or ETX categories and a variety
of covariates (age, gender, baseline atherosclerosis, or in the multivariate analysis: age, gender, baseline atherosclerosis, hypertension, apolipoprotein AI, apolipoprotein B,
pack-years of smoking, fibrinogen, ferritin, body mass index, alcohol consumption, and serum protein).
*Odds ratio calculated for a 1-SD unit change in plasma ETX; cases 5 subjects with incident atherosclerosis; AS 5 atherosclerosis.
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tween ETX and atherosclerosis was not appreciably differ-
ent at distinct levels of vascular risk factors.
A total of 220 men and women showed laboratory and/or
clinical evidence of one or more chronic bacterial infections
and/or clinical conditions associated with frequent episodes
of infections: recurrent urinary tract infections (n 5 25),
chronic bronchitis (n 5 77), asthma (n 5 15), emphysema
(n 5 141), recurrent upper respiratory tract infections (n 5
9), chronic gastrointestinal infections (including Helicobacter
pylori) (n 5 7) and periodontal infections (n 5 39). Mean
serum c-reactive protein level was 0.32 mg/dl in subjects
with ETX levels #50 pg/ml, and 0.64 mg/dl in subjects
with ETX .50 pg/ml (p 5 0.03). As expected, ETX level
emerged as a prominent risk predictor of incident athero-
sclerosis in this subgroup. Predictive significance of high
ETX according to smoking status and presence of infectious
diseases is summarized in Figure 5. Highest priority was
obtained for smokers with manifest infections, mainly
smoker’s bronchitis followed in descending order by smok-
ers without evidence of infectious disease and nonsmoking
subjects with bacterial infections. In subjects with ETX
levels #50 pg/ml, chronic infection significantly increased
risk of incident atherosclerosis (OR [odds ratio] 5 1.6; p 5
0.034).
Finally, once incident cardiovascular disease (n 5 38 of 516)
was substituted for incident atherosclerosis as the outcome
measure, results were similar. Endotoxin level .50 pg/ml
emerged as a significant risk predictor, with the association
being more pronounced in smokers and subjects with infec-
tious diseases (age/gender-adjusted hazard ratio at 95% CI
[confidence interval], 2.3 [1.1 to 5.1]). Exclusion of men and
women with cardiovascular disease prevalent at the 1990
baseline (n 5 47) yielded similar results (age/gender-adjusted
hazard ratio at 95% CI, 3.9 [1.2 to 12.7]). These results should
be viewed in light of the comparatively low number of subjects
with incident cardiovascular disease, which precludes multivar-
iate adjustment and further subgroup analysis.
DISCUSSION
Infections and atherosclerosis. The possibility that infec-
tious agents crucially contribute to early atherogenesis was
first proposed in the late 1970s based on animal-
experimental research (Mark’s disease model) and recently
experienced a resurgence of interest (10,21–24). Elevated
level of C-reactive protein, an indicator of ongoing inflam-
mation, was reported to predict a high risk of atherosclerotic
disease in apparently healthy men (9,10,21,25). The bulk of
seroepidemiologic studies supported an involvement of
common chronic infections in atherogenesis (10,24). Special
focus was on herpes viridae, gram-negative bacteria (Heli-
cobacter pylori, Chlamydia pneumoniae) and chronic dental
Figure 3. Risk of incident carotid atherosclerosis associated with
endotoxin levels .50 pg/ml in nonsmokers, ex-smokers, and
current smokers. **p , 0.01 for effect modification; OR 5 odds
ratio; AS 5 atherosclerosis.
Figure 4. Age- and gender-adjusted incidence of carotid athero-
sclerosis according to endotoxin level and smoking status. AS 5
atherosclerosis. **p , 0.01; n.s. 5 not significant (vs. nonsmokers
with endotoxin #50 pg/ml).
Figure 5. Risk of incident carotid atherosclerosis associated with
endotoxin levels .50 pg/ml according to smoking status and
presence of infectious diseases. The p values were derived from
multivariate logistic regression analysis (*p , 0.05; **p , 0.01).
OR 5 odds ratio; AS 5 atherosclerosis.
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infections (2,10,26–30). Preliminary results from two inter-
ventional trials suggested beneficial effects of macrolid
antibiotics on the course of coronary heart disease (31,32).
All these studies, however, did not furnish proof that
infections are causally related to atherosclerotic disease and
not simply an epiphenomenon or a commensal without
pathological relevance (24,33).
Lack of a consensus in this important field originates
mainly from the fact that the nature of infectious attack
against human vasculature remains obscure. Potential
pathophysiological mechanisms include direct infection of
the arterial wall (33,34), inference of acute-phase response
with blood clotting (procoagulant state) and homocystein
metabolism, and induction of autoimmunity (35–38). In
addition, endotoxemia may cause endothelial dysfunction in
the course of severe systemic infections, thus driving vascu-
lature into a pro-atherogenic mode (response-to-injury
hypothesis) (33,39). Lipopolysaccharides from Escherichia
coli augment the expression of endothelial adhesion mole-
cules and subsequent leukocyte adherence (40–42) and rank
among the classic activators of cytokine production in
atheroma (6,43,44). Further atherogenic properties include
induction of intravascular coagulation and lowering of
HDL, which is a natural scavenger of ETX (45). Exposure
of human volunteers to ETX provokes prolonged stunning
of the endothelium in vivo (5). In all, atherogenic capacity
of bacterial ETX is experimentally well-founded but has so
far attracted only limited attention for its putatively rare
occurrence in human circulation (sepsis). A recent survey
unexpectedly suggested a commonplace occurrence of, in
part, high ETX levels in apparently healthy elderly subjects
(7) and thus shed new light on the possibility of ETX
involvement in atherogenesis.
Association of endotoxin with atherosclerosis. Our study
is among the first to assess in a systematic fashion plasma
levels of bacterial ETX in the general population. Blood
specimens from virtually all subjects contained ETX though
at highly variable concentrations (Fig. 1). A considerable
proportion even exhibited levels higher than 50 pg/mL
without evidence of underlying severe systemic illness.
Endotoxemia originates from episodes of bacterial translo-
cation (chronic infections or colonization), inhalation of
ETX in cigarette smoke or gut barrier dysfunction (7,8).
The assay system applied in the current study identifies
lipopolysaccharides from chlamydia, E. coli, Helicobacter and
Haemophilus, to name only a few (15), and it thus mirrors a
broad spectrum of gram-negative bacteria. As an outstand-
ing finding, baseline endotoxemia emerged as one of the
strongest risk predictors of five-year incidence of carotid
atherosclerosis and cardiovascular disease in our survey. The
risk burden afforded by high ETX levels was mainly
confined to levels beyond 50 pg/ml (90th percentile; Fig. 2)
and applied to subjects with chronic infection and cigarette
smoking (Table 2, Fig. 5). Notably, prediction significance
of ETX declined in strength after smoking cessation but did
not normalize within a five-year period (Fig. 3), which is in
close agreement with a recent comparable cohort study (46).
This finding fits well into the concept that it is not
smoking itself (exposure to nicotine and other smoke
ingredients) but chronic bronchial infections and/or bacte-
rial colonization that represent the actual atherogenic cul-
prit. Elevation of C-reactive protein and clinical evidence of
infection usually persist for several years after quitting (25).
In this context, high coincidence of smoking and chronic
chlamydial infections merits attention. The significance of
chronic minor infections in the mediation of smoking effects
on atherosclerosis is substantiated by our finding that the
incidence of carotid atherosclerosis was no higher in current
and ex-smokers with ETX concentrations lower than 50
pg/ml than in non-smokers (Fig. 4). All these subjects faced
only a moderate base risk of atherosclerosis, whereas smok-
ers and ex-smokers with high ETX almost obligatorily
developed new atherosclerotic lesions (Fig. 4). In other
words, ETX measurements permitted us to identify smokers
at high risk of incident atherosclerosis in our population.
The predictive significance of high ETX was more pro-
nounced in smokers with manifest bronchitis but also
extended to those without clinical (and laboratory) evidence
of infectious disease (Fig. 5).
As anticipated, subjects with various chronic and recur-
rent bacterial infections constitute a second large population
in which high ETX predicts a markedly elevated risk of
incident carotid atherosclerosis. Assessment of infectious
diseases, even when performed with maximum effort and
best possible precision, remains subject to diagnostic inac-
curacies. Results should be interpreted in the light of these
potential limitations.
Finally, in nonsmokers without detectable infections,
ETX levels higher than 50 pg/ml were rare and did not
show a clear association with incident atherosclerosis. This
may well be a matter of low statistical power but may also
arise from poor estimation of long-term exposure to ETX
by a single measurement in this subgroup.
Study limitations. Several limitations of our study deserve
further consideration: first, there is no consensus on how to
measure plasma ETX concentrations. The assay system
applied (LAL) detects a broad spectrum of bacterial ETX
and showed adequate performance in previous studies (15).
It bears the disadvantage of undetermined interlaboratory
variability and is not approved for use in clinical practice.
Therefore, analyses have been performed on deciles of
levels, thus enabeling reproducibility for other laboratories
that may define their own risk ranges (i.e., upper decile of
risk). Second, the level of ETX in human circulation is
subject to substantial changes and consequently to high
measurement variability. However, inaccuracies in assessing
risk (independent) variables tend to weaken true relations
rather than create spurious ones.
Conclusions. Endotoxemia is a promising candidate risk
factor of atherosclerosis and cardiovascular disease and
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probably represents a pathophysiological link in the associ-
ation among cigarette smoking, chronic infections and
atherosclerosis. Biological plausibility, consistency of results,
strength of association and the prospective study design all
advocate such an interpretation of our results. Nevertheless,
the possibility that endotoxemia is only a surrogate for the
actual (unknown) atherogenic agent in infectious disease
cannot ultimately be ruled out.
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